- Home
- DOMO vs DCTH Comparison
DOMO vs DCTH Comparison
Compare DOMO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- DCTH
- Stock Information
- Founded
- DOMO 2010
- DCTH 1988
- Country
- DOMO United States
- DCTH United States
- Employees
- DOMO N/A
- DCTH N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- DCTH Medical/Dental Instruments
- Sector
- DOMO Technology
- DCTH Health Care
- Exchange
- DOMO Nasdaq
- DCTH Nasdaq
- Market Cap
- DOMO 286.1M
- DCTH 352.0M
- IPO Year
- DOMO 2018
- DCTH N/A
- Fundamental
- Price
- DOMO $7.42
- DCTH $11.97
- Analyst Decision
- DOMO Hold
- DCTH Strong Buy
- Analyst Count
- DOMO 5
- DCTH 4
- Target Price
- DOMO $10.10
- DCTH $21.50
- AVG Volume (30 Days)
- DOMO 408.2K
- DCTH 345.3K
- Earning Date
- DOMO 12-05-2024
- DCTH 11-08-2024
- Dividend Yield
- DOMO N/A
- DCTH N/A
- EPS Growth
- DOMO N/A
- DCTH N/A
- EPS
- DOMO N/A
- DCTH N/A
- Revenue
- DOMO $318,458,000.00
- DCTH $22,644,000.00
- Revenue This Year
- DOMO $0.94
- DCTH $1,605.13
- Revenue Next Year
- DOMO N/A
- DCTH $111.67
- P/E Ratio
- DOMO N/A
- DCTH N/A
- Revenue Growth
- DOMO 0.01
- DCTH 945.91
- 52 Week Low
- DOMO $6.11
- DCTH $3.70
- 52 Week High
- DOMO $12.23
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- DOMO 40.72
- DCTH 57.26
- Support Level
- DOMO $6.92
- DCTH $10.75
- Resistance Level
- DOMO $7.81
- DCTH $13.30
- Average True Range (ATR)
- DOMO 0.47
- DCTH 0.75
- MACD
- DOMO -0.10
- DCTH -0.08
- Stochastic Oscillator
- DOMO 17.12
- DCTH 47.82
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.